IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 290, 339, 393 & 530**

NOTICE OF ADJOURNMENT OF AUCTION AND SALE HEARING FOR THE REMAINING ASSETS

PLEASE TAKE NOTICE OF THE FOLLOWING:

On June 23, 2026, Sangamo Therapeutics, Inc., as debtor and debtor in possession (the "**Debtor**") in the above-captioned case, filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code with the United States Bankruptcy Court for the District of Delaware (the "**Court**").

On July 14, 2026, the Court entered the *Order (A) Approving Bidding Procedures for the Sale of the Debtor's Assets, (B) Approving the Debtor's Entry into the Stalking Horse APAs and Granting Bid Protections, (C) Authorizing the Debtor to Designate Additional Stalking Horse Bidders and Granting Bid Protections, (D) Approving Assumption and Rejection Procedures, (E) Scheduling an Auction and Sale Hearing and Approving Forms and Manner of Notice Thereof, and (F) Granting Related Relief* [Docket No. 122] (the "**Bidding Procedures Order**"), which, among other things, approved procedures (the "**Bidding Procedures**")[2] to be used in connection with one or more Sales of the Debtor's Assets.

On August 19, 2026 and August 27, 2026, respectively, the Debtor filed the *Notice of Extended Bid Deadline for (I) Remaining Assets and (II) Plan Sponsor Alternative Bids* [Docket No. 339] and the *Notice of Further Extension of Bid Deadline for (I) Remaining Assets and (II) Plan Sponsor Alternative Bids* [Docket No. 393] (the "**Second Extension Notice**"). As set forth in the Second Extension Notice, the Debtor, in accordance with the Bidding Procedures, extended the Bid Deadline with respect to any Bids for the Remaining Assets and Plan Sponsor Alternative Bids through and including the date upon which an order of the Court confirming a chapter 11 plan in the Chapter 11 Case becomes a final, non-appealable order, and indicated that the Debtor intended to file a chapter 11 plan on or before September 25, 2026. The Debtor did not file a

[1] The debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The debtor's mailing address is 470 Noor Ave., Suite B #1306, South San Francisco, CA 94080.

[2] Capitalized terms used but not defined herein have the meanings given to them in the Bidding Procedures or the Bidding Procedures Order, as applicable.

2610989261116000000000017

chapter 11 plan on or before September 25, 2026 and, on October 2, 2026, the Debtor paid off the Replacement DIP Facility made available to the Debtor by Future Solutions Investments, LLC.

On October 21, 2026, the Debtor filed the *Notice of Revised Bid Deadline, Auction, and Sale Hearing for the Remaining Assets* [Docket No. 530], pursuant to which the Debtor, following consultation with the Official Committee of Equity Holders (the "**Equity Committee**") and the Official Committee of Unsecured Creditors (the "**Creditors' Committee**"), and in accordance with the Bidding Procedures, (i) reestablished the Bid Deadline for the Remaining Assets for **November 13, 2026 at 5:00 p.m. (Eastern Time)**, (ii) scheduled the Auction, if necessary, for the Remaining Assets for **November 17, 2026 at 10:00 a.m. (Eastern Time)** and (iii) scheduled a Sale Hearing, if necessary, for the Court to consider the sale of the Remaining Assets for **November 23, 2026 at 10:00 a.m. (Eastern Time)**.

By the reestablished Bid Deadline, the Debtor received bids for certain subsets of the Remaining Assets, which the Debtor, in consultation with the Equity Committee and the Creditors' Committee, continues to review. Accordingly, in the exercise of its business judgment and after consultation with the Equity Committee and the Creditors' Committee, **the Debtor has adjourned the Auction and the Sale Hearing for the Remaining Assets to a date and time to be determined.**

Copies of the Bidding Procedures Motion, the Bidding Procedures Order, and the Bidding Procedures, may be obtained free of charge by visiting the Verita Website https://www.veritaglobal.net/sangamotherapeutics.

[*Remainder of page intentionally left blank*]

Dated: November 16, 2026
Wilmington, Delaware

/s/ James F. McCauley

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
James F. McCauley (No. 6991)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
mccauley@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession